Overview
PFSA market data
Price History
PFSA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$110.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.86 – $1,297.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $497.7K.
Company News
Profusa shares are trading lower after the company announced a 1-for-4 reverse stock split.Benzinga · Aug 13, 2026, 1:26 PM
Profusa Announces 1-For-4 Reverse Stock Split Effective August 17Benzinga · Aug 13, 2026, 11:06 AM
Profusa shares are trading lower after the company obtained the right and option, but not the obligation, to buy diagnostics firm G3 Vision Labs.Benzinga · Aug 3, 2026, 1:17 PM
Profusa Enters Option Agreement To Buy G3 Vision Labs And Affiliates; Has Right To Buy 100% Of G3 Vision LabsBenzinga · Jul 31, 2026, 9:00 PM
Profusa shares are trading lower after the company announced the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company.Benzinga · Jul 27, 2026, 2:14 PM
Why Is Profusa Stock Falling Monday?Benzinga · Jul 27, 2026, 11:46 AM
Profusa Appoints Jack Stover As Executive Chairman And CEOBenzinga · Jul 27, 2026, 10:12 AM
Profusa To Merge With Privately Held, Commercial-Stage Health Diagnostics And Toxicology Testing Company; Profusa To Issue 19.99% Stake to The Company And Will Issue Convertible Prefs; Combined Entity Operate As Public Diagnostics FirmBenzinga · Jul 27, 2026, 10:05 AM
Profusa Files Resale Prospectus For Offer And Resale From Time To Time Of Up To 7,170,891 Shares Of Common Stock By Selling StockholdersBenzinga · Jul 7, 2026, 12:55 PM
Profuse Announces 1-For-25 Reverse Stock Split, Effective July 7Benzinga · Jul 2, 2026, 3:10 PM